| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/23/2002 | WO2002040671A2 Immunoglobulin superfamily proteins |
| 05/23/2002 | WO2002040666A2 Fat regulated genes, uses thereof, and compounds for modulating same |
| 05/23/2002 | WO2002040517A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040505A2 Dibenzoxazepine alpha v integrin receptor antagonist |
| 05/23/2002 | WO2002040486A2 METHODS OF TREATING p38 KINASE-ASSOCIATED CONDITIONS AND PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS |
| 05/23/2002 | WO2002040485A1 Preventive or therapeutic medicines for diabetes containing fused-heterocycle compounds or their salts |
| 05/23/2002 | WO2002040475A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040469A1 Bombesin receptor antagonists |
| 05/23/2002 | WO2002040457A1 Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor |
| 05/23/2002 | WO2002040456A1 Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor |
| 05/23/2002 | WO2002040450A1 (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
| 05/23/2002 | WO2002040448A1 Pyridone derivatives as ap2 inhibitors |
| 05/23/2002 | WO2002040446A1 Glucagon antagonist/inverse agonist |
| 05/23/2002 | WO2002040445A1 Glucagon antagonists/inverse agonists |
| 05/23/2002 | WO2002040444A1 Glucagon antagonists/inverse agonists |
| 05/23/2002 | WO2002040039A2 In vivo use of water absorbent polymers |
| 05/23/2002 | WO2002040038A2 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | WO2002040037A2 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | WO2002040035A1 Remedies for diabetes |
| 05/23/2002 | WO2002040034A1 Complexes of phosphate derivatives |
| 05/23/2002 | WO2002040033A1 Formulation containing phosphate derivatives of electron transfer agents |
| 05/23/2002 | WO2002040019A1 Benzimidazole derivatives |
| 05/23/2002 | WO2002040014A1 Fat composition for oral or enteral administration and hexacosanoic acid depressant |
| 05/23/2002 | WO2002040012A1 Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms |
| 05/23/2002 | WO2002040010A1 Nateglinide-containing hydrophilic drug preparations |
| 05/23/2002 | WO2002040007A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | WO2002039997A2 Ace-2 modulating compounds and use thereof |
| 05/23/2002 | WO2002039988A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | WO2002039984A2 Medicine based on anti-hyperglycaemic microcapsules with prolonged release |
| 05/23/2002 | WO2002039978A1 Supplement to be enterally administered for parenteral nutrition or partial enteral/oral nutrition of the critically ill, the chronically ill and people with malnutrition |
| 05/23/2002 | WO2002039954A2 Novel compounds |
| 05/23/2002 | WO2002039834A1 Nutritional composition for an immune condition |
| 05/23/2002 | WO2001092253A3 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 05/23/2002 | WO2001089494A3 Use of zolendronate for the manufacture of a medicament for the treatment of bone metabolism diseases |
| 05/23/2002 | WO2001087882A3 Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors |
| 05/23/2002 | WO2001087284A3 Aldosterone antagonist composition for release during aldosterone acrophase |
| 05/23/2002 | WO2001080828A3 Improved water-insoluble drug particle process |
| 05/23/2002 | WO2001079444A3 Albumin fusion proteins |
| 05/23/2002 | WO2001074394A8 New combination of a betablocker and a cholesterol-lowering agent |
| 05/23/2002 | WO2001047946A9 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 05/23/2002 | WO2001044206A9 Pyrazine based inhibitors of glycogen synthase kinase 3 |
| 05/23/2002 | WO2001041760A9 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect |
| 05/23/2002 | WO2001035941A3 Novel composition based on a thiazolidinedione and metformin and use |
| 05/23/2002 | WO2001022953A3 Use of retigabin for treating neuropathic pain |
| 05/23/2002 | WO2000063204A3 Substituted azoles |
| 05/23/2002 | WO2000054765A8 Method of treating eating disorders |
| 05/23/2002 | US20020062024 Hetero-tetrahydroquinolines |
| 05/23/2002 | US20020062022 Processes for preparation of cyclopenta [b] [1,4] diazepino [6,7,1-hi] indoles and derivatives |
| 05/23/2002 | US20020062008 Novel human beta2 integrin alpha subunit |
| 05/23/2002 | US20020061923 Diacid isoindoleine amide derivative |
| 05/23/2002 | US20020061921 Novel compounds |
| 05/23/2002 | US20020061920 Selected fused pyrrolocarbazoles |
| 05/23/2002 | US20020061918 Benzyl isooxazole and benzyl pyrazole derivatives as aldose reductase and cyclooxygenase-2 inhibitors |
| 05/23/2002 | US20020061914 Benzothiazole, benzooxazole and benzoimidazole derivatives as sodium or calcium channel modulators |
| 05/23/2002 | US20020061911 Enantiomers of 6-amino EM-12 and method of use |
| 05/23/2002 | US20020061910 Optically pure reboxetine or its methanesulfonate salt inhibits reuptake of norepinephrine |
| 05/23/2002 | US20020061904 Hydroxyesters of 7-desmethylrapamycin |
| 05/23/2002 | US20020061901 HMG-CoA reductase inhibitors and method |
| 05/23/2002 | US20020061887 For therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis |
| 05/23/2002 | US20020061883 3-thioxo-[1,2,4]-oxadiazinan-5-one derivatives |
| 05/23/2002 | US20020061877 Substituted cyclic amine metalloprotease inhibitors |
| 05/23/2002 | US20020061853 Caspase inhibtors and uses thereof |
| 05/23/2002 | US20020061840 Tripeptide compounds useful as selective inhibitors of aminopeptidase A and corresponding pharmaceutical compositions |
| 05/23/2002 | US20020061302 Method for the treatment of diabetes |
| 05/23/2002 | US20020061292 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 05/23/2002 | CA2763223A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | CA2448729A1 Piperazinyl and piperidyl substituted heterocyclic compounds |
| 05/23/2002 | CA2436854A1 Pyridone derivatives as ap2 inhibitors |
| 05/23/2002 | CA2429897A1 M. tuberculosis chaperonin 10 and uses thereof |
| 05/23/2002 | CA2429894A1 M. tuberculosis chaperonin 60.1 and uses thereof |
| 05/23/2002 | CA2429628A1 Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| 05/23/2002 | CA2429455A1 Fat regulated genes, uses thereof, and compounds for modulating same |
| 05/23/2002 | CA2429329A1 Bombesin receptor antagonists |
| 05/23/2002 | CA2429195A1 Immunoglobulin superfamily proteins |
| 05/23/2002 | CA2429067A1 Preventive or therapeutic medicines for diabetes containing fused-heterocycle compounds or their salts |
| 05/23/2002 | CA2428787A1 Benzimidazole derivatives |
| 05/23/2002 | CA2428782A1 Medicine based on anti-hyperglycaemic microcapsules with prolonged release and its method of preparation |
| 05/23/2002 | CA2428754A1 Corticotropin releasing factor receptor 2 deficient mice and uses thereof |
| 05/23/2002 | CA2428647A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 05/23/2002 | CA2428527A1 (dihydro)isoquinoline derivatives as phosphodiesterase inhibitors |
| 05/23/2002 | CA2428519A1 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists |
| 05/23/2002 | CA2426089A1 Bombesin receptor antagonists |
| 05/23/2002 | CA2425117A1 Dibenzoxazepine alpha v integrin receptor antagonist |
| 05/23/2002 | CA2406925A1 Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms |
| 05/22/2002 | EP1207161A1 Novel isoindole derivatives |
| 05/22/2002 | EP1207158A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 05/22/2002 | EP1207157A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 05/22/2002 | EP1207156A1 Substituted benzylthiazolidine-2,4-dione derivatives |
| 05/22/2002 | EP1206939A1 Cholesterol-lowering agents, secondary bile acid procuction inhibitors and foods and drinks |
| 05/22/2002 | EP1206936A2 Phenylacetic acid compositions for treating or preventing hypercholesterolemia |
| 05/22/2002 | EP1206569A2 Method of screening for triacyglycerol hydrolase inhibitors |
| 05/22/2002 | EP1206553A2 Isomerase proteins |
| 05/22/2002 | EP1206544A2 Odorant-binding human proteins fixing hydrophobic ligands: polypeptides and polynucleotides coding for said polypeptides and uses thereof |
| 05/22/2002 | EP1206541A1 Dendritic enriched secreted lymphocyte activation molecule |
| 05/22/2002 | EP1206485A2 New effectors of dipeptidyl peptidase iv for topical use |
| 05/22/2002 | EP1206467A1 N-heterocyclic derivatives as nos inhibitors |
| 05/22/2002 | EP1206457A1 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| 05/22/2002 | EP1206448A1 Novel vitamin d analogues |
| 05/22/2002 | EP1206283A2 Improved cellular uptake of bioactive agents |
| 05/22/2002 | EP1206262A1 Npy antagonists: spiroisoquinolinone derivatives |